Abstract
OBJECTIVE: The objective of this study was to evaluate complications of Greenfield (Boston Scientific, Marlborough, Mass) stainless steel inferior vena cava (IVC) filters on follow-up computed tomography (CT) imaging and to elucidate associated risk factors.
METHODS: Ninety-three patients with CT studies obtained for other reasons after Greenfield IVC filter placement (2007-2014) were retrospectively studied. Greenfield filters were placed permanently in those with venous thromboembolism and an expected lifelong contraindication to anticoagulation or life expectancy <6 months.
RESULTS: A total of 190 follow-up CT imaging studies were available for review. In total, filter-associated IVC thrombus (n = 10 [10.7%]) and pulmonary embolism breakthrough (n = 4 [4.3%)] were documented by contrast-enhanced CT. Perforation was evident in 18 patients (19.4%) with an average indwelling time of 256 days. No symptomatic perforation and no strut fracture were documented. There was no significant difference in perforation rate with respect to age of the patient (P = .61), sex (P = 1.00), or history of malignant disease (P = .40). The filter perforation rate and number of perforating struts were significantly higher in patients with longer indwelling time (>90 days) than in patients with shorter indwelling time (<90 days;90 days were significantly smaller than those of nonperforated patients (284 vs 358 mm2; P < .01).
CONCLUSIONS: Stainless steel Greenfield filters remain a relatively safe option for patients requiring permanent mechanical filtration.
PMID: 32063523 [PubMed - as supplied by publisher]
23:24
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
23:25
In reply to this message
pubmed: caandvteortroorpul
Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
Related Articles
Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting.
J Oncol Pharm Pract. 2020 Feb 16;:1078155220901777
Authors: Yassine D, Brown EN, Putney D, Fasoranti O
PMID: 32063102 [PubMed - as supplied by publisher]
23:25
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
23:25
In reply to this message
pubmed: caandvteortroorpul
Cancer related venous thromboembolism: both a complication and negative prognostic indicator.
Related Articles
Cancer related venous thromboembolism: both a complication and negative prognostic indicator.
Gastroenterology. 2020 Feb 13;:
Authors: Ghukasyan R, Donahue TR
PMID: 32061863 [PubMed - as supplied by publisher]
23:25
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
23:25
In reply to this message
pubmed: caandvteortroorpul
Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--media.wiley.com-assets-7388-68-wiley-free-full-text.png //www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.ncbi.nlm.nih.gov-corehtml-pmc-pmcgifs-pubmed-pmc.png Related Articles
Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation.
Cancer Med. 2019 01;8(1):455-462
Authors: Baker HA, Brown AR, Mahnken JD, Shireman TI, Webb CE, Lipe BC
No comments:
Post a Comment
اكتب تعليق حول الموضوع